Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of
pregnant women after the 20th week of gestation. An excess of placental expressed …

Preeclampsia is a hypertensive pregnancy disease associated with a massive increase in
sFlt-1 (soluble form of the vascular endothelial growth factor 1) in the maternal circulation …

Background Preeclampsia is a hypertensive syndrome that complicates 3% to 5% of
pregnancies in the United States. Preeclampsia originates from an improperly vascularized …

Background—Targeted therapies to stabilize the clinical manifestations and prolong
pregnancy in preeclampsia do not exist. Soluble fms-like tyrosine kinase 1 (sFlt-1), an …

Preeclampsia is characterized by the development of elevated blood pressure during the
second and third trimesters of pregnancy that is accompanied by end organ dysfunction. The …

Background Preeclampsia remains one of the most serious complications of pregnancy.
Effective therapies are yet to be developed. Recent research has identified an imbalance of …

Preeclampsia (PE) is a serious pregnancy complication, affecting about 5–7% of
pregnancies worldwide and is characterized by hypertension and damage to multiple …

Preeclampsia is a common obstetric complication globally responsible for a significant
burden of maternal and perinatal morbidity and mortality. The anti-angiogenic protein, sFLT …

Preeclampsia is a pregnancy-induced hypertensive disorder resulting from abnormal
placentation, which causes factors such as sFlt-1 to be released into the maternal …

Soluble fms‐like tyrosine kinase‐1 (sFlt1), a circulating vascular endothelial growth factor
receptor 1 antagonist, is associated with the pathogenesis of pre‐eclampsia. Extracorporeal …